216 related articles for article (PubMed ID: 34657748)
1. Monoclonal antibody based radiopharmaceuticals for imaging and therapy.
Lin M; Paolillo V; Le DB; Macapinlac H; Ravizzini GC
Curr Probl Cancer; 2021 Oct; 45(5):100796. PubMed ID: 34657748
[TBL] [Abstract][Full Text] [Related]
2. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.
Martiniova L; Zielinski RJ; Lin M; DePalatis L; Ravizzini GC
Cancer J; 2022 Nov-Dec 01; 28(6):446-453. PubMed ID: 36383907
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunoconjugates for the treatment of cancer.
Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Eugène T; Pallardy A; Frampas E; Carlier T; Ferrer L; Gaschet J; Davodeau F; Gestin JF; Faivre-Chauvet A; Barbet J; Chérel M
Semin Oncol; 2014 Oct; 41(5):613-22. PubMed ID: 25440606
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunoimaging and radioimmunotherapy: will these be routine procedures?
Bischof Delaloye A
Semin Nucl Med; 2000 Jul; 30(3):186-94. PubMed ID: 10928382
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Immuno-PET: a navigator in monoclonal antibody development and applications.
van Dongen GA; Visser GW; Lub-de Hooge MN; de Vries EG; Perk LR
Oncologist; 2007 Dec; 12(12):1379-89. PubMed ID: 18165614
[TBL] [Abstract][Full Text] [Related]
7. [Radioimmunotargeting: diagnosis and therapeutic use].
Vuillez JP
Bull Cancer; 2000 Nov; 87(11):813-27. PubMed ID: 11125290
[TBL] [Abstract][Full Text] [Related]
8. Immuno-PET for Clinical Theranostic Approaches.
Bailly C; Cléry PF; Faivre-Chauvet A; Bourgeois M; Guérard F; Haddad F; Barbet J; Chérel M; Kraeber-Bodéré F; Carlier T; Bodet-Milin C
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036044
[TBL] [Abstract][Full Text] [Related]
9. High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents prior to 131I-radioimmunotherapy.
Verel I; Visser GW; Vosjan MJ; Finn R; Boellaard R; van Dongen GA
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1645-52. PubMed ID: 15290121
[TBL] [Abstract][Full Text] [Related]
10. The promise of immuno-PET in radioimmunotherapy.
Verel I; Visser GW; van Dongen GA
J Nucl Med; 2005 Jan; 46 Suppl 1():164S-71S. PubMed ID: 15653665
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on metals-based radioimmunotherapy (RIT): moving forward.
White JM; Escorcia FE; Viola NT
Theranostics; 2021; 11(13):6293-6314. PubMed ID: 33995659
[TBL] [Abstract][Full Text] [Related]
12. New insights into the pretargeting approach to image and treat tumours.
Patra M; Zarschler K; Pietzsch HJ; Stephan H; Gasser G
Chem Soc Rev; 2016 Nov; 45(23):6415-6431. PubMed ID: 27722526
[TBL] [Abstract][Full Text] [Related]
13. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer.
Divgi CR
Oncology (Williston Park); 1996 Jun; 10(6):939-53; discussion 954, 957-8. PubMed ID: 8823804
[TBL] [Abstract][Full Text] [Related]
14. PET Radiopharmaceuticals for Personalized Medicine.
Sharma S
Curr Drug Targets; 2016; 17(16):1894-1907. PubMed ID: 27440185
[TBL] [Abstract][Full Text] [Related]
15. Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.
Goldenberg DM; Juweid M; Dunn RM; Sharkey RM
J Nucl Med Technol; 1997 Mar; 25(1):18-23; quiz 34. PubMed ID: 9239599
[TBL] [Abstract][Full Text] [Related]
16. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
17. Current status and perspectives in alpha radioimmunotherapy.
Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629
[TBL] [Abstract][Full Text] [Related]
18. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
19. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.
Sharkey RM; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Semin Nucl Med; 2010 May; 40(3):190-203. PubMed ID: 20350628
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
